BridgeBio PharmaBBIO announced that the FDA has accepted its regulatory filing seeking approval for the investigational oral candidate encaleret to treat individuals living with a rare genetic endocrine disorder called autosomal dominant hypocalcemia type 1 (ADH1).
A final decision is expected by May 8, 2027. If approved, encaleret would become the first FDA-approved therapy specifically indicated for ADH1, offering a disease-targeted treatment for a condition that is currently managed with calcium and active vitamin D supplementation rather than therapies that address its underlying cause.
The FDA also notified BridgeBio that it is not currently planning to hold an advisory committee meeting, suggesting that the agency does not presently see the need for external expert review of the application. While this is generally viewed as a positive procedural development, it should not be interpreted as an indication of the FDA's ultimate approval decision.
The filing is supported by results from the phase III CALIBRATE study, which showed that encaleret led to the simultaneous restoration of blood and urine calcium, as well as the restoration of physiologic parathyroid hormone (PTH) production. Per BridgeBio, the findings support the drug’s potential as a disease-modifying therapy by targeting the underlying genetic cause of ADH1.
BBIO Stock’s Price Performance
Year to date, the company’s shares have gained 8% against the industry’s 5% fall.
Image Source: Zacks Investment Research
BridgeBio Takes a Step Closer to Becoming a Multi-Product Company
The FDA's acceptance of encaleret marks another regulatory milestone for BridgeBio as it continues to expand its product portfolio beyond Attruby, which is currently its only marketed product. The drug is approved for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
However, the company has several late-stage candidates that could significantly diversify its revenue base over the next 12 months. Encaleret is one of three near-term commercialization opportunities, alongside BBP-418 and infigratinib.
A filing for BBP-418 is already under FDA review for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a final decision expected by Nov. 27, 2026. On the other hand, BridgeBio is on track to submit a filing to the agency for infigratinib as a potential treatment for achondroplasia in the third quarter of 2026.
Together with encaleret, BBP-418 and infigratinib could significantly diversify BridgeBio's revenue base. If approved, these candidates would transform the company from a single-product business into a diversified rare disease commercial player, reducing its dependence on Attruby as its primary growth driver.
BBIO’s Zacks Rank
BridgeBio currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share (EPS) have increased from $2.97 to $3.02. Over the same period, EPS estimates for 2027 have also increased from $4.81 to $4.92. LQDA shares have skyrocketed more than 150% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed once, with the average surprise being 54.40%.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 EPS have increased from $3.20 to $3.30. Over the same period, EPS estimates for 2027 have risen from $3.64 to $3.87. HRMY shares have lost nearly 7% year to date.
Harmony Biosciences’ earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 25.16%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.